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Abstract
The article represents the combined treatment results analysis of 50 patients with deep vein thromboses of inferior vena cava
system. The complex clinical and instrumental examination of patients included duplex ultrasound scan, X-ray phlebography,
multislice computed tomography with intravenous contrast and radionuclide fleboscintigrahpy. All patients were performed
the regional thrombolytic therapy, combined with an open palliative thrombectomy in 19 (38%) patients and endovascular
implantation of a temporary or constant cava-filter in 31 (62%) patients. In postoperative period for 12 months’ monitoring the
local and general complications after combined treatment were found in 4 (8.0%) out of 50 patients, who were performed the
combined treatment.
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Problem statement and analysis of the
recent research
Venous thromboembolic complications (VTEC), including
deep vein thrombosis and pulmonary embolism, are the actual
problem of modern medicine, being one of the major causes
of death and invalidization [1, 2, 3, 4].
In 2004, thanks to the application of epidemiological cal-
culations model, 317 thousand deaths related to pulmonary
embolism were diagnosed in the general population of 454
million people in six European Union countries, 34% of cases
remained undiagnosed. In 59% of cases pulmonary embolism
was diagnosed only after death and only 7% of patients set
the correct diagnosis of pulmonary embolism alive [5, 6].
ICOPER register, which included 2,454 patients from 52 cen-
ters in 7 countries of the European Union, presented the mor-
tality from pulmonary embolism at the level of 17.4%, which
was evaluated in terms of 90 days after discharge from the
hospital [5, 7]. The European Society of Cardiology (2014)
forecast a doubling of cases of pulmonary embolism in pa-
tients older than 40 years during each of the next decade [5].
Pulmonary embolism mortality (PE) reaches 2.1 – 50%
in case of deep vein thrombosis (DVT) [8, 9] and in case of
resuscitation need the mortality increases to 65% [9]. There
often occurs a lightning form of pulmonary embolism – in
31.2 - 43.6% of cases [10].
Every year in Ukraine 50,000 episodes of PE are regis-
tered, the level of mortality is 20 – 25% of general hospital
mortality [7].
Important fact is that only in 10 – 20% of patients, who
died as a result of pulmonary embolism, symptoms of DVT are
diagnosed [7, 9], and in 9.2 – 50% of patients with proximal
DVT, at the moment of the appeal for medical help, at least one
episode of asymptomatic pulmonary embolism was already
noted [9]. During next 10 years after the first episode of
pulmonary embolism in 30% of patients relapse of pulmonary
embolism is observed, the greatest danger of relapse is found
in terms of 6 to 12 months after the first episode of pulmonary
embolism [10].
Despite of the best efforts, problem of venous thromboem-
bolism remains unresolved. Conservative anticoagulant ther-
apy, which was proposed by majority of foreign and national
authors, does not allow the reduction of the incidence of pul-
monary embolism and doesn’t reduce the manifestations of
postthrombosis syndrome. Surgical treatment of deep vein
thrombosis effectively prevents VTEC, but because of the late
appeal for medical care, opportunities to perform adequate and
complete thrombectomy and to prevent the posttrombolitic
changes in the late period are limited.
Regional thrombolytic therapy (RTLT) is an alternative
way of restoration of patency of thrombolized deep veins.
The effectiveness of thrombolytic therapy significantly de-
pends on several factors: time of thrombotic occlusion, it’s
location, length, thrombolytic drug and way of administra-
tion. Objective: to determine the efficacy of the combined
methods of the treatment of the deep vein thromboses of the
inferior vena cava system and the prophylaxis of the venous
thromboembolytic complications.
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1. Materials and methods
We have analyzed the examination and combined treatment
results of 50 patients with thrombosis of the inferior vena
cava (IVC) system in the Department of Vascular Surgery
of Transcarpathian Regional Clinical Hospital named after
A.Novak for period of 2006 – 2016 years. Men were 18
patients (36.0%) and women were 32 patients (64.0%). The
age of patients ranged from 29 to 72 years, average age – was
54±2.3 years.
All the patients had regional thrombolytic therapy (RTLT),
which was combined with an open palliative thrombectomy
in 19 (38%) patients and endovascular implantation of a tem-
porary or constant cava-filter in 31 (62%) patients (Table 1).
For the examination of patients the laboratory and instru-
mental methods were used: ultrasound Doppler and ultra-
sound duplex scanning (“ULTIMA PRO-30, z.one Ultra”,
ZONARE Medical Systems Inc., USA), radiographic contrast
phlebography (DSA, Integris-2000, Philips), multislice com-
puted tomography with intravenous contrast (Somatom CRX
“Siemens”, Germany, 1994) and radioisotope phleboscintigra-
phy (emission computed tomography “Tamara”).
2. Results and discussion
The duration of the disease has a prior importance for the out-
come of treatment. The most effective RTLT is in the earliest
period of thrombosis, which, in our opinion, does not exceed
3 – 5 days, when its application allows to save an unaltered
intima and venous valves. This feature dramatically reduces
contingent of potential patients, for whom the method can be
used, because usually quite a long latent period precedes the
time of severe clinical manifestations of the disease. Before
and after the planned RTLT, besides ultrasound or CT angio
regime, the patient was administered a general analysis of
blood and urine, biochemical blood analysis, blood group and
Rh-factor determinarion, coagulogram (PTI, fibrinogen, INR),
a blood test for D-dimer. For the RTLT in case of thrombosis
of deep vein of pelvis and lower limbs, we used mainly access
through posterior tibialis vena, in which after venotomy con-
ductor was set, and then the catheter. All interventions were
performed in operation room with X-ray-control. Through
the installed introducer, a conductor and diagnostic catheter
was injected endovasculary. The end of the catheter is in-
stalled in the affected vessel, and then the conductor should
be removed. Radiographic soluble contrast is administered
through applied catheter using angiographic injector or sy-
ringe, to identify the localization and extent of thrombosis. If
the catheter easily passed through the thrombotic masses, the
diagnostic catheter was replaced with thrombolytic catheter
with multiple openings. If the catheter was easily introduced
in X-ray control drirectly into the thrombotic masses, but there
was no possibility to bring it through the thrombotic masses,
it was replaced with aspiration one, and the tip of catheter was
installed near proximal end of thrombotic masses. Then it was
slowly removed from thrombotic masses, while introducing
thrombolytic solution. During thrombolytic therapy catheter
position was daily controlled as the lysis of thrombotic masses,
every time setting the catheter at last 3 – 5 cm more distally to
proximal border of residual thrombus. RTLT includes several
thrombolytic introduction techniques:
1. regional perfusion of the drug, which can be done in
two ways: nonselective (end of the catheter is prox-
imally to occlusion and does not reach the areas of
thrombosis) or selective (end of the catheter is adjacent
to the thrombotic masses);
2. intrathrombotic infusion, during which the end of the
catheter penetrates the thrombus, and the operator per-
forms thrombolytic administration;
3. intrathrombotic bolus infusion, in which the end of the
catheter is placed distally to thrombosis zone; for this
method we use catheter with side holes;
4. gradual infusion, during which the operator at first sets
the end of the catheter near proximal end of thrombotic
masses and conducts thrombolytic infusion, and then,
gradually to the dissolution, end of the catheter is placed
distally to complete dissolution of blood clot;
5. prolonged infusion – a standard technique, during which
a catheter is installed in the affected area for a long time,
during which a thrombolytic agent is administered by
pump for microinfusions;
6. graded infusions – thrombolytic agent is injected bo-
lusly in highly concentrated dose, which rapidly dis-
solves fresh blood clots;
7. forced periodic infusion – catheter is placed inside the
thrombus, thrombolytic agent is administered bolusly
in large doses every 20 – 30 seconds; the catheter is
gradually tighten according to dissolution of thrombotic
masses.
Mostly we use a combination of several methods of ad-
ministration of thrombolytic drug, which we have mentioned
above. After finishing the infusion, angiography was per-
formed through selectively installed catheter to assess the
outcome of the procedure. In case of satisfactory results, we
have finished the procedure. If the result was doubtful, the
patient was transferred to the Department of Anesthesiology
and Intensive Care, and catheter was placed in the throm-
bosis area and gradual infusion of thrombolytic drug using
a microinfusion pump was performed. During the patient’s
stay in the Department of Anesthesiology and Intensive Care,
constant monitoring of vital functions of the patient and co-
agulation parameters were conducted (PTI, fibrinogen, INR).
If the bleeding was suspected (presence hemorrhage on the
tongue, mouth cavity, blood in urine or in stool) or in case
of severe coagulopathy, infusion of thrombolytic drug was
stopped immediately. After 12 hours control angiography was
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Table 1. Combined treatment of patients of main group
Top of thrombotic/masses
Tibial veins Popliteal veins Femoral veins Iliac veins Total
Combined treatment
RTLT Implantation of cava-filter 3 7 2 5 7 19 19 19 31 50Surgical thrombectomy 4 3 12 - 19
perfomed through the catheter which was installed before. In
case of positive outcome, operation was stopped. If the results
were unsatisfactory, operation was continued for another 12
hours in Department of Anesthesiology and Intensive Care,
but not more than 24 hours in total.
After finishing the procedure, catheter and introducer were
removed. Defect of vessel in place of punction was closed
with a device for hemostasis or by using manual compression,
at least for 40 minutes. Results were evaluated by ultrasound
at the 1-st and the 2-nd days after the procedure.
The effectiveness of the procedure was indicated by: restora-
tion of patency of the vessel not less than for 30%, which is
confirmed by instrumental methods of research; absebce of
complications; restoration of function of the affected area
(reduction of pain and swelling).
In 39 patients (78%) the posterior tibial vein was used.
In case of segmental femoral or iliac vein thrombosis and
passable distal vein in 11 patients (22%) we used a needle
catheter infusion through the femoral or popliteal vein in
antegrade direction using the traditional Seldinger method.
As thrombolytic drug we have used streptokinase (n=33)
and alteplase (n=17). In case of using streptokinase, its dosage
was as following: during first 30 minutes – 250 thousand units
intravenously, followed by 100 thousand units every hour for
24 – 72 hours. Total amount of the used drug was 2.65 – 7.45
million units of streptokinase for the course of RTLT.
In case of using alteplase (“Aktelize” produced by the com-
pany “Boehringer Ingelheim”), treatment was started with bo-
lus intravenous administration of 5 mg for 2 minutes and then
continued infusion with a speed of 1 mg/hour for 1 - 3 days
before the appearance of angiographic signs of restoration of
patency of the affected vein segments. The total number of
alteplase administered to treatment was 25 - 75 mg.
After finishing RTLT patient was administered low molec-
ular weight heparin at therapeutic doses based on patient body
weight, or rivaroxaban/dabigatran in therapeutic doses. Ri-
varoxaban was administered at the dose of 20 mg – once per
day, and dabigatran 150 mg – twice per day for 3 - 6 - 12
months.
During the conducted RTLT, fibrinogen level should be
between 1.5 - 2 g/l. By reducing the level of fibrinogen to 2 g/l
or lower, infusion rate of trombolitic drug was reduced twice
(until increased fibrinogen level). By reducing the levels of
fibrinogen to 1.5 g/l, RTLT was stopped and heparin infusion
was started under the control of activated partial thrombo-
plastin time. Indexes of coagulation were evaluated every 6
hours.
During RTLT there was a real danger of PE in system
of vena cava inferior (VCI) that is why for the prevention of
complications in 31 patients (62%) endovascular implantation
of a temporary or permanent cava-filter (CF) was used. Im-
plantation of CF in lumen of VCI allows to delay all particles
ranging in size from 2 to 4 mm, depending on the design of
the filter, that significantly reduces the risk of VTEC, but does
not affect the flow in the VCI. Temporary CF was established
in 28 patients (90.3%), permanent in 3 (9.7%). Indications for
implantation of permanent CF were recurrent pulmonary em-
bolism on the background of repeated DVT. In case of implan-
tation of a permanent CF in 2 patients CF “Osot” (Ukraine)
and in 1 patient CF “Cordis TrapEase” was used.
Duration of intervention usually does not exceed 40 – 60
minutes. CF was implantated distallly to renal veins under con-
trol of X-ray after finishing of diagnostic angiographic study,
through percutaneous access through the femoral (n=27) or
subclavicular (n=4) veins under local anesthesia. Transporta-
tion of CF was performed using the catheter with size from
5 to 11 Fr through introducer with size from 6 to 12 Fr. The
length of the catheter-conductor was 65 cm (for subclavicular
access) or 85 cm (for femoral). Using a special device, CF was
moved into the lumen of the vessel and fixed to its walls. Un-
der X-ray control CF was placed at level of L1 - L2 vertebra.
Before endovascular implantation of CF, we’ve necessarily
calculated the size of VCI using ultrasound, for the purpose
of personal selection of CF according to VCI diameter and to
prevent its migration. After setting CF during X-ray control,
necessarily evaluated the place of implantation of the filter, its
location in relation to the longitudinal and transversal axis of
the vessel, absence of perforation of vessels (contrast output
beyond vessels).
After implantation of CF within 1 - 2 days limitation of
physical activity and bed rest were prescribed. After finishing
of the RTLT, indirect anticoagulants and venotonics were
administered (normoven 1 tab. 2 times a day after meals for 2
months), application of elastic bandage, clinical supervision
of vascular surgeon at least 1 time per month with ultrasound
control of CF status.
In order to set endovascular implantation we used CF of
the following brands: REPTELA (n=10), Osot (n=8) (Figure
1), Greenfield (n=4) (Figure 2) and Cordis (n=9) (Figure 3).
Cava-filters “Osot”, which are producted by Endomed
(Ukraine), are produced since 1996 year. CF “Osot” consists
of eighteen arched curved legs, which in one end are collected
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(a) (b)
Figure 1. Endovascular implantation of cava-filter “Osot” in the inferior vena cava: deployment of filter construction (a), final
form (b).
(a) (b)
Figure 2. Endovascular implantation of cava-filter Greenfield in the inferior vena cava: conductor in the lumen of vein (a),
deployment of cava-filter construction (b).
in holder and are placed in two layers (for 9 feet). In a work-
ing condition CF is fixed by legs in the wall of blood vessels,
which are putting pressure on the wall of vessel due to elastic
deformation forces. CF “Osot” is produced in two versions –
temporary (with loop on the end of filter holder for extraction)
and permanent filters (without loop). Legs of CF are placed
in the direction of blood flow, so the filter element “crowding
out” the embolus to the periphery of the vessel and leaving a
significant portion of the lumen of VCI free, which reduces
barriers to blood flow and reduces the risk of formation of
cava-syndrome. Temporary CF “Osot” was implanted in 6 pa-
tients. In 2 patients, as it was mentioned above, we performed
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implantation of permanent CF.
In 1 patient we implanted permanent KF “Cordis Tra-
pEase”. In 8 patients we implanted a modified construction of
CF “Cordis” for temporary implantation “OptEase”, which is
distinguished by hook on the caudal end for removing. Period
for removing CF “Cordis OptEase” is limited to 12 days.
Duration of temporary implantation of CF is ranged widely
from 12 to 80 days, in average it was 39.5 days. Thus, using
of temporary CF “Osot” and “Cordis OptEase” duration of its
implantation does not exceed 12 - 14 days, “Greenfield” – 45
- 50 days, REPTELA – 70 - 80 days. Indications for removing
of temporary CF were not only the manufacturer’s recommen-
dations, but presense of persuasive evidence of absence of a
danger of pulmonary embolism. After receiving information
about liquidation of danger of PE, temporary CF was removed
by endovascular intervention under X-ray control.
To reduce the amount of thrombotic masses, artificial
recanalization, creating better conditions for thrombolysis
and release of the major collectors in 19 patients we used
a combination of surgical thrombectomy and RTLT. After
thrombectomy, even in case of uncompletely freed vein lu-
men from the thrombotic masses, in conditions of artificial
recanalization, contact of drug with thrombus was in a much
larger area. Surgery intervention improves venous outflow
from the affected limb and local hemodynamics. Role of
RTLT after surgical thrombectomy is to attempt to perform
complete dezobstruction of main veins of limbs and preven-
tion of rethrombosis in the nearest postoperative period (Table
2).
Combination of thrombectomy with RTLT, unlike isolated
thrombectomy, allowed restoring deep vein lumen and pre-
venting the postthromboflebityc syndrome in patients with
DVT. Mostly RTLT was performed after open thrombectomy
of the femoral vein – in 12 patients. Less often RTLT was
performed after thrombectomy of tibial and popliteal veins
– in 4 and 3 patients, respectively. Open thrombectomy and
RTLT were performed with the help of method, described
above.
After the combined treatment in postoperative period for
12 months of observation the local and general complications
were found in 4 (8.0%) out of 50 patients, who completed the
combined treatment.
In 2 patients after open thrombectomy from common
femoral vein followed by RTLT, we have observed the limfor-
rhea from postoperative wound in the groin, which has solely
stopped after 11and 15 days respectively. In 1 patient marginal
necrosis was observed in the area of wound in the groin. There
were no purulent-septic complications in the postoperative
wounds. In 1 patient during the first 4 days after the beginning
of RTLT, short-term local bleeding and small subcutaneous
bruising in the area of injection were observed, which were
eliminated with more prolonged compression of the injection
sites. Bleedings of other genesis and other complications in
the immediate postoperative period were not observed.
Length of patients’ stay in hospital after combined treat-
ment of thrombosis of IVC systems ranged from 12 to 16
days, an average of 13±1.3 days. There were no lethal cases.
Conclusions
1. Combined treatment is effective and justified in the
treatment of common forms of venous thrombosis of
the inferior vena cava system, but it needs further im-
provement and development.
2. The most safe in means of bleeding complications are
the options when surgical intervention is preceded by
thrombolysis or is executed during the actual interven-
tion.
3. The best prospect is the combination of several meth-
ods of blood flow restoration for different segments
(primarily open thrombectomy) and the temporary pre-
vention of pulmonary thromboembolism (application
of temporary cava-filters models).
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Figure 3. Endovascular implantation of cava- filter “Cordis OptEase” in the inferior vena cava.
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